{
    "clinical_study": {
        "@rank": "16819", 
        "arm_group": [
            {
                "arm_group_label": "Oxygen", 
                "arm_group_type": "Active Comparator", 
                "description": "oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m"
            }, 
            {
                "arm_group_label": "Sham oxygen", 
                "arm_group_type": "Placebo Comparator", 
                "description": "sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the effect of nocturnal oxygen therapy during a\n      stay at moderate altitude on exercise performance of patients with chronic obstructive lung\n      disease."
        }, 
        "brief_title": "Patients With Chronic Obstructive Pulmonary Disease at Altitude - Effect of Nocturnal Oxygen on Exercise Performance", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Obstructive Pulmonary Disease (COPD)", 
        "condition_browse": {
            "mesh_term": [
                "Lung Diseases", 
                "Respiration Disorders", 
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients with moderate to severe COPD living below 800 m, will be recruited to participate\n      in a randomized cross-over field trial evaluating the hypothesis that exercise capacity\n      during a 2 day sojourn at moderate altitude is improved by nocturnal oxygen therapy via a\n      nasal cannula. Outcomes will be assessed during 2 days in Zurich (490 m, low altitude\n      baseline), and during 2 days at St. Moritz Salastrains (2048 m)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  chronic obstructive pulmonary disease (COPD), GOLD grade 2-3\n\n          -  residents at low altitude (<800 m)\n\n        Exclusion Criteria:\n\n          -  unstable condition, COPD exacerbation\n\n          -  mild (GOLD 1) or very severe COPD (GOLD 4)\n\n          -  requirement for oxygen therapy at low altitude residence\n\n          -  hypoventilation\n\n          -  pulmonary hypertension\n\n          -  more than mild or unstable cardiovascular disease\n\n          -  use of drugs that affect respiratory center drive\n\n          -  internal, neurologic or psychiatric disease that interfere with protocol compliance\n             including current heavy smoking (>20 cigarettes per day), inability to perform 6 min\n             walk test.\n\n          -  previous intolerance to moderate altitude (<2600m).\n\n          -  exposure to altitudes >1500m for >2 days within the last 4 weeks before the study.\n\n          -  pregnant or nursing patients"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02143609", 
            "org_study_id": "2013-0088V2A3"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Oxygen", 
                    "Sham oxygen"
                ], 
                "description": "Nocturnal nasal oxygen during stay at 2048 m", 
                "intervention_name": "oxygen", 
                "intervention_type": "Drug", 
                "other_name": "Nocturnal oxygen via nasal cannula, 3 L/min, at 2048 m"
            }, 
            {
                "arm_group_label": [
                    "Oxygen", 
                    "Sham oxygen"
                ], 
                "description": "Sham oxygen (room air) via nasal cannula, 3 L/min, at 2048 m", 
                "intervention_name": "sham oxygen (room air)", 
                "intervention_type": "Drug", 
                "other_name": "Nocturnal nasal room air during stay at 2048 m"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "airway disease", 
            "bronchitis", 
            "emphysema", 
            "lung"
        ], 
        "lastchanged_date": "May 27, 2014", 
        "location": {
            "contact": {
                "email": "konrad.bloch@usz.ch", 
                "last_name": "Konrad E Bloch, MD", 
                "phone": "+41 44 255 3828"
            }, 
            "facility": {
                "address": {
                    "city": "Zurich", 
                    "country": "Switzerland", 
                    "zip": "CH-8091"
                }, 
                "name": "University Hospital Zurich, Pulmonary Division"
            }, 
            "investigator": {
                "last_name": "Konrad E Bloch, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Switzerland"
        }, 
        "number_of_arms": "2", 
        "official_title": "Patients With Chronic Obstructive Pulmonary Disease at Altitude - Effect of Nocturnal Oxygen Therapy on Exercise Performance", 
        "overall_contact": {
            "email": "konrad.bloch@usz.ch", 
            "last_name": "Konrad E Bloch, MD", 
            "phone": "+41 44 255 3828"
        }, 
        "overall_contact_backup": {
            "email": "tsogyal.latshang@usz.ch", 
            "last_name": "Tsogayl D Latshang, MD", 
            "phone": "+41 44 255 3828"
        }, 
        "overall_official": {
            "affiliation": "University Hospital, Z\u00fcrich", 
            "last_name": "Konrad E Bloch, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Switzerland: Ethikkommission", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Difference in the distance walked in 6 min between the oxygen and sham oxygen period", 
            "measure": "6 min walk distance", 
            "safety_issue": "No", 
            "time_frame": "Day 2 at 2048 m"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02143609"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Difference in the distance walked in 6 min between the oxygen and sham oxygen period", 
                "measure": "6 min walk distance", 
                "safety_issue": "No", 
                "time_frame": "day 3 at 2048 m"
            }, 
            {
                "description": "Difference in arterial oxygen partial pressure, carbon dioxide partial pressure, and pH", 
                "measure": "Arterial blood gas analysis", 
                "safety_issue": "No", 
                "time_frame": "Day 2 at 2048 m"
            }, 
            {
                "description": "Difference in spirometric variables between the oxygen and sham oxygen period", 
                "measure": "Spirometry", 
                "safety_issue": "No", 
                "time_frame": "Day 2 at 2048 m"
            }, 
            {
                "description": "Difference in perceived exertion rated with the BORG CR10 scale at the end of the 6 min walk", 
                "measure": "Perceived exertion", 
                "safety_issue": "No", 
                "time_frame": "Day 2 at 2048 m"
            }, 
            {
                "description": "Difference in perceived exertion rated with the BORG CR10 scale at the end of the 6 min walk", 
                "measure": "Perceived exertion", 
                "safety_issue": "No", 
                "time_frame": "Day 3 at 2048 m"
            }, 
            {
                "description": "Number of participants in whom arterial oxygen saturation measured by pulse oximetry is less than 75% for more than 30 min during the oxygen and sham oxygen treatment periods at 2028 m.", 
                "measure": "Severe hypoxemia", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 to 3 at 2048 m"
            }
        ], 
        "source": "University of Zurich", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Zurich", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}